Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Inflammatory Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: Romidepsin|DRUG: Abraxane
Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborators: Celgene Corporation